UFI - UNIFI INC （）

Final cumulative pooled IBD safety data support the longstanding safety profile of STELARA across all IBD approved indications Additional long term extension data demonstrate more than half of STELARA-treated patients with ulcerative colitis achieved clinical remission, clinical response, and/or demonstrated endoscopic improvement at four years SPRING HOUSE, Pa. , March 4, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA ® (ustekinumab) through five years in adults with moderately to severely active Crohn''s disease (CD) and four years in adults with moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extension (LTE) study evaluating the efficacy of STELARA for the treatment of adults with moderately to severely active UC. 1,2 These data are a part of Janssen''s 22 oral and poster presentations at the 18 th Congress of the European Crohn''s and Colitis Organization (ECCO), taking place in Copenhagen, Denmark , March 1-4 . "These data reinforce the known efficacy and safety profile of STELARA, and demonstrate it can be an effective long-term treatment option for patients living with moderately to severely active ulcerative colitis," said UNIFI study author Waqqas Afif , M.D., Associate Professor, Department of Medicine, Division of Experimental Medicine and Division of Gastroenterology at McGill University Health Centre in Montreal, Canada . a "Importantly, clinical and endoscopic outcomes reinforce the durable efficacy of STELARA, as we remain committed to developing therapies that provide patients with lasting remission." Final STELARA long-term pooled safety analysis (Oral presentation OP39): 1 A final pooled safety analysis of six Phase 2/3 IBD studies included 2,575 patients treated with STELARA and a total of 4,826 patient-years (PY) of follow-up.

Unifi, Inc. (NYSE: UFI) (together with its consolidated subsidiaries, “UNIFI”), makers of REPREVE and one of the world’s leading innovators in recycled and synthetic yarns, today released its Sustainability Report for fiscal 2022. The Report provides expanded insight into UNIFI’s industry leading sustainability strategy and the Company’s responsible approach to creating long-term value

Excess inventory in clothing retailers is crushing near-term demand for Unifi''s yarns. Read more to see why I''m still bullish on UFI stock.

Unifi, Inc. [UFI] Q2 2023 Earnings Conference Call February 2, 2023 8:30 AM ETCompany ParticipantsAlbert Carey - Executive ChairmanEddie Ingle - CEOCraig Creaturo - CFOA.J.

https://www.investing.com/news/pro/cjs-securities-upgrades-unifi-inc-to-market-outperform-432SI-2994388

Final cumulative pooled IBD safety data support the longstanding safety profile of STELARA across all IBD approved indications Additional long term extension data demonstrate more than half of STELARA-treated patients with ulcerative colitis achieved clinical remission, clinical response, and/or demonstrated endoscopic improvement at four years SPRING HOUSE, Pa. , March 4, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA ® (ustekinumab) through five years in adults with moderately to severely active Crohn''s disease (CD) and four years in adults with moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extension (LTE) study evaluating the efficacy of STELARA for the treatment of adults with moderately to severely active UC. 1,2 These data are a part of Janssen''s 22 oral and poster presentations at the 18 th Congress of the European Crohn''s and Colitis Organization (ECCO), taking place in Copenhagen, Denmark , March 1-4 . "These data reinforce the known efficacy and safety profile of STELARA, and demonstrate it can be an effective long-term treatment option for patients living with moderately to severely active ulcerative colitis," said UNIFI study author Waqqas Afif , M.D., Associate Professor, Department of Medicine, Division of Experimental Medicine and Division of Gastroenterology at McGill University Health Centre in Montreal, Canada . a "Importantly, clinical and endoscopic outcomes reinforce the durable efficacy of STELARA, as we remain committed to developing therapies that provide patients with lasting remission." Final STELARA long-term pooled safety analysis (Oral presentation OP39): 1 A final pooled safety analysis of six Phase 2/3 IBD studies included 2,575 patients treated with STELARA and a total of 4,826 patient-years (PY) of follow-up.

Unifi, Inc. (NYSE: UFI) (together with its consolidated subsidiaries, “UNIFI”), makers of REPREVE and one of the world’s leading innovators in recycled and synthetic yarns, today released its Sustainability Report for fiscal 2022. The Report provides expanded insight into UNIFI’s industry leading sustainability strategy and the Company’s responsible approach to creating long-term value

Excess inventory in clothing retailers is crushing near-term demand for Unifi''s yarns. Read more to see why I''m still bullish on UFI stock.

Unifi, Inc. [UFI] Q2 2023 Earnings Conference Call February 2, 2023 8:30 AM ETCompany ParticipantsAlbert Carey - Executive ChairmanEddie Ingle - CEOCraig Creaturo - CFOA.J.

https://www.investing.com/news/pro/cjs-securities-upgrades-unifi-inc-to-market-outperform-432SI-2994388

Unifi has seen a sharp downturn in volumes as apparel companies have cut orders. See why I still believe there is a bullish case to be made for UFI stock.

Unifi (UFI) announced a major expansion of its innovative Textile Takeback program

GREENSBORO, N.C.--(BUSINESS WIRE)--Today, Unifi Inc. (NYSE: UFI), makers of REPREVE® and one of the world’s leading innovators in recycled and synthetic yarns, announced a major expansion of its innovative Textile Takeback™ program. The initiative is designed to collect and recycle polyester-based fabric waste, including both pre- and post-consumer fabrics, and transform it into REPREVE® – the leading recycled performance fiber that powers top brands and sustainable goods worldwide. With millio

Today, Unifi Inc. (NYSE: UFI), makers of REPREVE and one of the world’s leading innovators in recycled and synthetic yarns, announced a major expansion of its innovative Textile Takeback program. The initiative is designed to collect and recycle polyester-based fabric waste, including both pre- and post-consumer fabrics, and transform it into REPREVE – the leading recycled performance fiber

Unifi, Inc. (NYSE:NYSE:UFI) Q1 2023 Earnings Conference Call November 4, 2022 8:30 AM Company Participants A Eaker - Vice President of Finance and Investor Relations Albert Carey -…